On September 9, Royalty Pharma plc fell 6.4% in regular trading, trading at $59.875/share, with turnover of $186 million. The stock has pulled back sharply from its prior close of $63.96 as investors unwound positions tied to an anticipated S&P 500 index inclusion.

On the news front, the S&P 500 index announced its latest quarterly rebalancing results after Friday's close. Analyst Melissa Roberts had previously listed Royalty Pharma plc as a leading candidate for inclusion, citing the company's total market capitalization of approximately $36.8 billion — well above the $22.7 billion minimum threshold. However, the expected inclusion did not materialize, prompting concentrated selling pressure in after-hours trading and into Monday's regular session.

The broader pharmaceutical sector traded lower in tandem. Among sector peers, Eli Lilly fell 2.45%, Novartis fell 13.91%, Johnson & Johnson fell 2.43%, Pfizer fell 1.96%, and AstraZeneca fell 1.76%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)